Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;2(4):441-6.
doi: 10.2147/vhrm.2006.2.4.441.

Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter?

J V Ian Nixon  1
Affiliations
Review

Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter?

J V Ian Nixon. Vasc Health Risk Manag. 2006.

Abstract

As the numbers of completed outcomes based clinical trials evaluating the use of statin drugs for the management of cardiovascular risk continue to increase, it is clear that the numbers of patients that may benefit from these drugs continues to grow. The recently published studies are reviewed in this summary. The distinction is made between patients requiring either primary or secondary cardiovascular preventive management. The review identifies the increasing numbers of patients who may benefit from the use of statins as primary preventive management, and the changing concepts of the utilization of statin drugs for secondary preventive management, including the more aggressive titration of the drugs to provide incremental improvement in patient outcomes. Available data on the use of statins in the elderly patient are reviewed, and observations are made regarding the intrinsic properties and adverse effects of the drugs.

PubMed Disclaimer

References

    1. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Education Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The Greek atorvastatin and coronary heart disease evaluation study (GREACE) Curr Med Res Opin. 2002;18:220–228. - PubMed
    1. Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504. - PubMed
    1. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicenter randomized placebo controlled trial. Lancet. 2004;364:685–96. - PubMed
    1. de Lemos JA, Blazing MA, Wiviott SD, et al. for the A to Z Investigators Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes. JAMA. 2004;292:1307–16. - PubMed
    1. Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group Primary Prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615–22. - PubMed

MeSH terms

Substances